Institut Stvolovykh Kletok Cheloveka PAO operates within the Health and allied services sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Institut Stvolovykh Kletok Cheloveka PAO with three other
health care providers in Europe:
Celyad Oncology SA
sales of 5,000.00 Euros [US$5,966.60 ]
of which 100%
Polski Bank Komorek Macierzystych SA
(211.25 million Polish New Zlotys [US$55.89 million]
of which 88%
was B2C), and
Vita 34 AG
based in GERMANY
(20.07 million Euros [US$23.95 million]
of which 73%
was Revenue from processing/manufacturing).
During the year ended December of 2020, sales at
Institut Stvolovykh Kletok Cheloveka PAO were 1.08 billion Russian Rubles (US$14.87 million).
increase of 29.7%
versus 2019, when the company's sales were 835.58 million Russian Rubles.
This was the fifth consecutive year of sales increases at Institut Stvolovykh Kletok Cheloveka PAO
(and since 2015, sales have increased a total of 249%).
Sales of Other Revenue saw an increase
that was more than double the company's growth rate: sales were up
2,756.9% in 2020, from
492,000.00 Russian Rubles to 14.06 million Russian Rubles.
Institut Stvolovykh Kletok Cheloveka PAO also saw significant increases in sales in
Sales of the Drug Neovaskulgen (up 87.8% to 140.61 million Russian Rubles)
Not all segments of Institut Stvolovykh Kletok Cheloveka PAO experienced an increase in sales in 2020:
sales of Project Services Genetico fell 16.3% to 328.96 million Russian Rubles.
Institut Stvolovykh Kletok Cheloveka PAO also experienced decreases in sales in
Sprs Service Therapy (down 10.8% to 35.44 million Russian Rubles)